Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Author:
Hiroaki KANZAKI
1
;
Yujin HOSHIDA
Author Information
- Publication Type:Reply to Correspondence
- From:Clinical and Molecular Hepatology 2025;31(1):e121-e122
- CountryRepublic of Korea
- Language:English
